Effect Of Rosiglitazone On The Growth Of Hunman Hepatocarcinoma Cells In Virto

Objective To investigate the effect of Rosiglitazone , the ligand ofPeroxisome Proliferator-activated Receptor gamma, on cell proliferation inhibition of hepatocarcinoma cells in vitro and its possible mechanism.Methods Human hepatocarcinoma SMMC7721 cell line was cultured invitro, Cultured SMMC7721 cells were designed into 12.5 μ mol/L RSG group, 25 μ mol/L RSG group, 50 μ mol/L RSG group, 100 μ mol/L RSG group and the control group, 10 μ mol/L ATRA group. Proliferation inhibition effect was tested by MTT assay; Flow cytometry was used to detect cell cycle and apoptosis rate; The activity of γ -GT was measured with γ -GT kit and the secretive AFP was measured with ELISA ; Expression of PPARγ, CyclinD₁ protein in hepatocarcinoma cells between untreated and treated with or without Rosiglitazone were observed by immunohistochemistry.Results Rosiglitazone at various concentrations of 12.5, 25, 50, 100μmol/L and All-trans retinoic acid at concentration 10 μmol·L^-1 could inhibit the proliferation of SMMC7721 cells, RSG inhibit the proliferation in a dose-dependent and time-dependent manner; Cell micrographys tended to be normal after treatment; the specific activities of γ-GT and the secretive amount of AFP was reduced; Flow cytometry analysis reavealed a cell cycle arrest at G1 phase ,but apoptosis rate was not changed remarkably; nuclear traslocation and up-regulation of PPARγ protein expression and the down -regulation of CyclinD protein expression were observed .Conclusion The ligand of PPARγ, Rosiglitazone induced significantly growth inhibition of human hepatocarcinoma SMMC7721 cells line in vitro which...